arrow
T

Tilmann Bochtler

german cancer research center and university of heidelberg
H指数:31
被引数:3,525

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

68Ga-FAPI-PET/CT in extra-cervical CUP: Head-to-Head Comparison of 68Ga-FAPI-46 with 18F-FDG in 13 patients

68Ga-FAPI-PET/CT在颈外CUP中的应用:68Ga-FAPI-46与18F-FDG的13例患者头对头比较

2026-05-220
OAAI
Neoadjuvant Atezolizumab and Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer: Efficacy and Safety Results of an Open-Label, Single-Arm, Phase II Trial

新辅助阿替利珠单抗联合化疗治疗非鳞非小细胞肺癌:一项开放标签、单臂、II期试验的疗效与安全性结果

2026-04-190
OAAI
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial

阿扎胞苷治疗具有可测量残留病灶的患者中的骨髓增生异常综合征/急性髓系白血病:RELAZA2试验的最终长期结果

Blood
IF23.1
2025-12-100
PRE
Outcomes of patients (pts) with unfavourable, nonsquamous cancer of unknown primary (CUP) progressing after induction chemotherapy (CTX) in the global, open-label, phase II CUPISCO study

CUPISCO全球开放标签II期研究中,接受诱导化疗(CTX)后进展的预后不良、非鳞癌来源不明肿瘤(CUP)患者的结局

2024-09-010
PRE
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study
LANCET
IF88.5
2024-08-018
PRE
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial
2023-10-2416
OAAI
Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP)
2023-10-0111
OA